Eravacycline (dihydrochloride)

Eravacycline dihydrochloride (TP-434 dihydrochloride) is a potent and broad-spectrum antibacterial agent.

Product Specifications

CAS Number

[1334714-66-7]

Product Name Alternative

TP-434 dihydrochloride; TP-434-046

UNSPSC

12352005

Hazard Statement

H361, H362

Target

Bacterial; Beta-lactamase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Eravacycline_dihydrochloride.html

Purity

98.88

Solubility

DMSO : ≥ 50 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(NC(C(O)=C1C2=O)=CC(F)=C1C[C@@]3([H])C[C@@]4([H])[C@H](N(C)C)C(O)=C(C(N)=O)C([C@@]4(O)C(O)=C32)=O)CN5CCCC5.[H]Cl.[H]Cl

Molecular Formula

C27H33Cl2FN4O8

Molecular Weight

631.48

Precautions

H361, H362

References & Citations

[1]Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.|[2]Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61 (7) .|[3]Xiao XY, et al. Fluorocyclines: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55 (2) :597-605.|[4]Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57 (11) :5548-58.|[5]Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59 (5) :2567-71.

Shipping Conditions

Dry Ice

Storage Conditions

-80°C, protect from light, stored under nitrogen

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

ACS Infect Dis. 2024 Dec 13;10 (12) :4127-4136.|Biomaterials. 2024 Sep 11:314:122815.|Cureus. 2024 Dec 1;16 (12) :e74917.|J Antibiot (Tokyo) . 2025 May;78 (6) :370-379.|J Antimicrob Chemother. 2021 Feb 11;76 (3) :653-658.|mBio. 2021 Jun 29;12 (3) :e0103121.|Microb Pathog. 2020 Dec;149:104502.|Microbiol Spectr. 2025 Oct 16:e0160325.|Pharmaceutics. 2021 Dec 5;13 (12) :2085.|Research Square Preprint. 2022 Feb.|Ann Lab Med. 2021 May 1;41 (3) :293-301.|Antibiotics (Basel) . 2022 Sep 23;11 (10) :1298.|Antimicrob Agents Chemother. 2019 May 24;63 (6) . pii: e00470-19.|Antimicrob Agents Chemother. 2021 May 18;65 (6) :e00203-21.|Antimicrob Agents Chemother. 2024 Mar 6;68 (3) :e0112023.|Clin Exp Pharmacol Physiol. 2023 Jul;50 (7) :604-609.|Diagn Micr Infec Dis. 2020 Nov;98 (3) :115129.|Infect Drug Resist. 2023 Apr 17:16:2271-2279.|Infect Drug Resist. 2023 Sep 8:16:6005-6015.|J Antibiot (Tokyo) . 2019 Aug;72 (8) :600-604.|J Antibiot (Tokyo) . 2022 Sep;75 (9) :498-508.|J Antimicrob Chemother. 2021 Jul 15;76 (8) :2071-2078.|J Clin Microbiol. 2020 Jan 28;58 (2) :e01603-19.|Microbiol Spectr. 2023 Feb 14;11 (1) :e0323822.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0071823.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Nat Struct Mol Biol. 2023 Sep;30 (9) :1380-1392.|Virulence. 2022 Dec;13 (1) :77-88.